News

Brief SummaryThis study will find out if a new medicine called NNC6019-0001 can help reduce the risk of heart-related death and illness in participants with a…

Trial Purpose and DescriptionThis is a Phase I/II, multi-center, open-label study designed to evaluate the safety, tolerability and efficacy of elranatamab in…

For East Asian adults with transthyretin amyloid cardiomyopathy (ATTR-CM), the approved therapy Amvuttra (vutrisiran) is a safe and effective treatment, with…

AbstractBackgroundLeft atrioventricular coupling index (LACI) has emerged as a powerful marker of cardiac remodeling across a variety of cardiac diseases, however…

The plasma protein transthyretin (TTR) transports retinol-binding protein and thyroxine1.Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive cause of…

Tafamidis (Vyndaqel/Vyndamax) stabilizes transthyretin (TTR) tetramer, preventing amyloidogenesis. It is the only approved disease-modifying therapy in ATTR…

Patisiran (Onpattro) and inotersen (Tegsedi) are TTR mRNA silencing therapies in hereditary ATTR amyloidosis (hATTR). Patisiran is lipid nanoparticle RNAi (siRNA),…

Acoramidis provides consistent clinical benefit in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM) irrespective of baseline atrial…

AbstractBackgroundAdvances in diagnosis and disease awareness have led to increased prevalence and incidence of transthyretin amyloid cardiomyopathy (ATTR‐CM), but…

AbstractIntroduction and objectives: To describe the clinical characteristics of patients with cardiac amyloidosis who have undergone heart transplantation (HT).…